Shortly after the first use of the mRNA COVID-19 vaccine (Comirnaty; Pfizer/BioNTech), it was noted that the rate of anaphylaxis to the vaccine (5–11 per million doses) is higher than after most other vaccines. This led to precautions in those with a history of polyethylene glycol (PEG) allergy and those who have an allergic reaction to their first dose. Experience has since been gathered which shows some of these people may proceed to vaccination.

This factsheet provides an update around management of those with allergic reactions to Comirnaty or a history of PEG allergy.